RU94035764A - Способ лечения онкологического заболевания - Google Patents

Способ лечения онкологического заболевания

Info

Publication number
RU94035764A
RU94035764A RU94035764/14A RU94035764A RU94035764A RU 94035764 A RU94035764 A RU 94035764A RU 94035764/14 A RU94035764/14 A RU 94035764/14A RU 94035764 A RU94035764 A RU 94035764A RU 94035764 A RU94035764 A RU 94035764A
Authority
RU
Russia
Prior art keywords
induced activity
oncology
disease treatment
radioactive
drug
Prior art date
Application number
RU94035764/14A
Other languages
English (en)
Other versions
RU2053776C1 (ru
Inventor
В.В. Кешелава
Original Assignee
В.В. Кешелава
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by В.В. Кешелава filed Critical В.В. Кешелава
Priority to RU94035764A priority Critical patent/RU2053776C1/ru
Priority to AU34882/95A priority patent/AU3488295A/en
Priority to PCT/RU1995/000195 priority patent/WO1996009075A1/ru
Application granted granted Critical
Publication of RU2053776C1 publication Critical patent/RU2053776C1/ru
Publication of RU94035764A publication Critical patent/RU94035764A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Способ лечения онкологического заболевания включает использование радиоактивного нуклида Fe наведенной активностью 0,8 мкКи на одну дозу препарата в виде таблетки в количестве 50 штук в течение 6 месяцев. Лечение по предлагаемому способу может проводится как самостоятельно, так и в сочетании с общеизвестными способами лечения рака. Учитывая определенную тропность опухолевых клеток к препаратам железа, радиоактивный нуклид Fe наведенной активностью 0,8 мкКи на одну дозу препарата может служить диагностическим средством в онкологии.

Claims (1)

  1. Способ лечения онкологического заболевания включает использование радиоактивного нуклида 5 9Fe наведенной активностью 0,8 мкКи на одну дозу препарата в виде таблетки в количестве 50 штук в течение 6 месяцев. Лечение по предлагаемому способу может проводится как самостоятельно, так и в сочетании с общеизвестными способами лечения рака. Учитывая определенную тропность опухолевых клеток к препаратам железа, радиоактивный нуклид 5 9Fe наведенной активностью 0,8 мкКи на одну дозу препарата может служить диагностическим средством в онкологии.
RU94035764A 1994-09-21 1994-09-21 Способ лечения онкологического заболевания RU2053776C1 (ru)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU94035764A RU2053776C1 (ru) 1994-09-21 1994-09-21 Способ лечения онкологического заболевания
AU34882/95A AU3488295A (en) 1994-09-21 1995-09-04 Method of treating malignant conditions
PCT/RU1995/000195 WO1996009075A1 (fr) 1994-09-21 1995-09-04 Procede de traitement d'affections malignes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94035764A RU2053776C1 (ru) 1994-09-21 1994-09-21 Способ лечения онкологического заболевания

Publications (2)

Publication Number Publication Date
RU2053776C1 RU2053776C1 (ru) 1996-02-10
RU94035764A true RU94035764A (ru) 1997-03-27

Family

ID=20160826

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94035764A RU2053776C1 (ru) 1994-09-21 1994-09-21 Способ лечения онкологического заболевания

Country Status (3)

Country Link
AU (1) AU3488295A (ru)
RU (1) RU2053776C1 (ru)
WO (1) WO1996009075A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174015C1 (ru) * 2000-11-21 2001-09-27 Кешелава Виктор Владимирович Препарат для лечения онкологического заболевания, способ его получения и применение

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5006329A (en) * 1988-01-22 1991-04-09 Cadema Medical Products, Inc. Radioactive tagged compounds and method for the treatment of metastatic bone cancer
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments
GB9115192D0 (en) * 1991-07-12 1991-08-28 Antisoma Ltd Cancer treatment
AU4953693A (en) * 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy

Also Published As

Publication number Publication date
AU3488295A (en) 1996-04-09
RU2053776C1 (ru) 1996-02-10
WO1996009075A1 (fr) 1996-03-28

Similar Documents

Publication Publication Date Title
D'Angio et al. Potentiation of x-ray effects by actinomycin D
Ingrand Characteristics of radio-isotopes for intra-articular therapy.
WO2005061009A3 (en) Microparticles for microarterial imaging and radiotherapy
IL122554A0 (en) Cascade polymer complexes process for their production and pharmaceutical agents containing said complexes
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
MY105482A (en) Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group.
ES8205231A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na
MY116474A (en) Potentiation of temozolomide in human tumour cells
SE9704549D0 (sv) Drug delivery system
DE69630727D1 (de) Radioaktiven Chitosankomplex und deren Anwendung in Strahlungstherapie
RU94035764A (ru) Способ лечения онкологического заболевания
Carey et al. The use of clomipramine in phobic patients: Preliminary research report.
Wolf et al. Current clinical trials for the treatment of adult Hodgkin’s disease: Common strategies and perspectives
CN108472556B (zh) 同位素制备方法
Lambin et al. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity
Weeks et al. Influence of plutonium concentration on effectiveness of therapeutic agents
SWEET JR et al. Disseminated malignant lymphoma, histiocytic type: the changing picture
DE60322191D1 (de) Intraduktale behandlung von brustläsionen umfassend therapeutische und diagnostische mittel
Cohen Treatment of small cell lung cancer: Progress, potential and problems
Bates A clinical evaluation of ICRF 159 as a radiosensitising agent
Daker Prospective chromosomal study of 30 patients undergoing 90Y synovectomy
Shopsin Bupropion (Wellbutrin®)-imipramine study: A single-blind comparison in depressed outpatients.
韩骅 et al. Significance of Translation and Transcription in the iRNAMediated LAI Reaction in vitro
RU94036142A (ru) Способ лечения опухолей
Gerner Biological effects of hyperthermia and interaction with radiation